(2-nitrobenzyl)(triphenyl)phosphonium chloride | 52513-28-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-nitrobenzyl)(triphenyl)phosphonium chloride
• 英文别名: o-nitrobenzyltriphenylphosphonium chloride；(2-nitro-benzyl)-triphenyl-phosphonium; chloride；(2-Nitro-benzyl)-triphenyl-phosphonium; Chlorid；o-Nitrobenzyl-triphenylphosphoniumchlorid；[(2-Nitrophenyl)methyl]triphenylphosphanium chloride；(2-nitrophenyl)methyl-triphenylphosphanium;chloride
• CAS: 52513-28-7
• 化学式: C₂₅H₂₁NO₂P*Cl
• 分子量: 433.874
• InChiKey: RBGSANDHIIMIOV-UHFFFAOYSA-M

物化性质

• 熔点：
  230 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  2.09
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2-nitrobenzyl)(triphenyl)phosphonium chloride 在 palladium on activated charcoal 氢气 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 tin(ll) chloride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 环己烷 、 甲苯 为溶剂， 20.0~125.0 ℃ 、413.68 kPa 条件下， 反应 64.25h， 生成 4-(2-aminophenyl)-9-methoxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
  参考文献：
  名称：

  4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure−Activity Relationships for Chromophore Modification and Phenyl Ring Substitution

  摘要：

  High-throughput screening has identified a novel class of inhibitors of the checkpoint kinase Wee1, which have potential for use in cancer chemotherapy. These inhibitors are based on a 4-phenylpyrrolo[3,4-c]carbazole- 1,3(2H,6H)-dione template and have been shown by X-ray crystallography to bind at the ATP site of the enzyme. An extensive study of the effects of substitution around this template has been carried out, which has identified substituents which lead to improvements in potency and selectivity for Wee1. While retention of the maleimide ring and pendant 4-phenyl group is necessary for potency, replacement of the carbazole nitrogen by oxygen is well tolerated and results in improved Wee1 selectivity against the related checkpoint kinase Chk1. Wee1 potency and selectivity are also enhanced by the incorporation of lipophilic functionality at the 2'-position of the 4-phenyl ring, and Wee1 selectivity against Chk1 is favored by C3-C5 alkyl substitution of the carbazole nitrogen. These studies provide a basis for the design of active analogues of the pyrrolocarbazole lead with improved physical properties.

  DOI：

  10.1021/jm0512591
• 作为产物：
  描述：

  2-硝基苄氯 、 三苯基膦 以 氯仿 为溶剂， 反应 72.0h， 以85%的产率得到(2-nitrobenzyl)(triphenyl)phosphonium chloride
  参考文献：
  名称：

  A Facile and Versatile Synthesis of 2-Substituted Tryptophans asN ^α-tert- Butyloxycarbonyl Derivatives

  摘要：

  2-取代吲哚与乙基α-亚硝基丙烯酸酯之间的Diels-Alder型环加成反应经过还原后，得到2-取代色氨酸酯。随后进行N-保护和皂化，得到适用于肽合成的相应Nα-保护2-取代色氨酸。此外，还描述了一种通过改良的Madelung合成法制备多种2-取代吲哚的方法。

  DOI：

  10.1055/s-1988-27471

文献信息

• Novel aminobenzoephenones
  申请人：——

  公开号：US20030119902A1

  公开（公告）日：2003-06-26

  The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.

  该发明涉及一种新型的氨基苯并酮衍生物类别，涉及包含该类化合物的药物制剂，涉及这种制剂的剂量单位，涉及包括给予该类化合物的治疗方法，以及涉及使用该类化合物制造药物制剂。
• Arylamine processes
  申请人：Coggan A. Jennifer

  公开号：US20070100164A1

  公开（公告）日：2007-05-03

  A process for the preparation of the tertiary arylamine compound, comprising reacting and arylhalide, such as am arylbromide, and an arylamine in an ionic liquid in the presence of a catalyst.

  一种制备三芳基胺化合物的方法，包括在催化剂存在下，在离子液体中反应芳基卤化物，如芳基溴化物，和芳胺。
• Photocyclization Reactions of Aryl Polyenes. IV. The Syntheses of Isatogens and Isatogen-like Compounds
  作者：Clifford C. Leznoff、Roger J. Hayward

  DOI：10.1139/v71-601

  日期：1971.11.15

  Photochemical reactions of 1-o-nitrophenyl-4-phenyl-1,3-butadiene, 1,4-di-o-nitrophenyl-1,3-butadiene, 1-o-nitrophenyl-6-phenyl-1,3,5-hexatriene, and 1,6-di-o-nitrophenyl-1,3,5-hexatriene all gave the appropriate 2-substituted isatogen. The related m- and p-nitrophenyl polyenes were inert to the irradiation conditions. A six-membered ring isatogen-like compound, 2-phenyl-3-oxo-benzo[d,e]quinoline-N-oxide was prepared by irradiation of 1-[1′-(8′-nitronaphthyl)]-2-phenylacetylene. A seven-membered ring isatogen-like compound, 6-phenyl-7-oxo-dibenzo[b,d]azepine-N-oxide, was prepared by heating 1-[2-(2′-nitrobiphenyl)]-2-phenylacetylene.

  1-o-硝基苯基-4-苯基-1,3-丁二烯、1,4-二-o-硝基苯基-1,3-丁二烯、1-o-硝基苯基-6-苯基-1,3,5-己三烯和1,6-二-o-硝基苯基-1,3,5-己三烯的光化学反应均生成了相应的2-取代异异烟酰胺。相关的m-和p-硝基苯基多烯对辐射条件不活性。通过辐射1-[1'-(8'-硝基萘基)]-2-苯基乙炔制备了一种类似异异烟酰胺的六元环化合物2-苯基-3-氧代苯并[d,e]喹啉-N-氧化物。通过加热1-[2-(2'-硝基联苯基)]-2-苯基乙炔制备了一种类似异异烟酰胺的七元环化合物6-苯基-7-氧代二苯并[b,d]氮杂环-N-氧化物。
• [EN] INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1)<br/>[FR] INHIBITEURS DE CHECKPOINT KINASES (WEE1 ET CHK1)
  申请人：WARNER LAMBERT CO

  公开号：WO2003091255A1

  公开（公告）日：2003-11-06

  This invention relates to pyrrolocarbazole derivatives according formula (I) wherein R1, R2, r7, R8 R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1.

  本发明涉及公式（I）中的吡咯并咔唑衍生物，其中R1，R2，r7，R8，R9，X和Y如规范中所定义，其中所述衍生物特异性地抑制检查点激酶Wee1和Chk1中的一个或两个。
• Novel prodrugs for phosphorus-containing compounds
  申请人：——

  公开号：US20020052345A1

  公开（公告）日：2002-05-02

  Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described: 1 wherein: V, W, and W′ are independently selected from the group consisting of —H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, optionally 1 heteroatom, substituted with hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both O groups attached to the phosphorus; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to one of said carbon atoms that is three atoms from an O attached to the phosphorus; together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; Z is selected from the group consisting of —CHR 2 OH, —CHR 2 OC(O)R 3 , —CHR 2 OC(S)R 3 , —CHR 2 OC(S)OR 3 , —CHR 2 OC(O)SR 3 , —CHR 2 OCO 2 R 3 , —OR 2 , —SR 2 , —CHR 2 N 3 , —CH 2 aryl, —CH(aryl)OH, —CH(CH═CR 2 2)OH, —CH(C≡CR 2 )OH, —R 2 , —NR 2 2 , —OCOR 3 , —OCO 2 R 3 , —SCOR 3 , —SCO 2 R 3 , —NHCOR 2 , —NHCO 2 R 3 , —CH 2 NHaryl, —(CH 2 ) p — OR 12 , and —(CH 2 ) p —SR 12 ; p is an integer 2 or 3; with the provisos that: a) V, Z, W, W′ are not all —H; and b) when Z is —R 2 , then at least one of V, W, and W′ is not —H, alkyl, aralkyl, or alicyclic; R 2 is selected from the group consisting of R 3 and —H; R 3 is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl; R 12 is selected from the group consisting of —H, and lower acyl; M is selected from the group that attached to PO 3 2− , P 2 O 6 3− , or P 3 O 9 4− is a biologically active agent, and is attached to the phosphorus in formula I via a carbon, oxygen, sulfur or nitrogen atom; and pharmaceutically acceptable prodrugs and salts thereof.

  本文描述了式I的前药、其用途、其中间体及其制备方法：其中：V、W和W′独立地选自由—H、烷基、芳基烷基、脂环烷基、芳香族、取代芳基、杂芳基、取代杂芳基、1-烯基和1-炔基组成的群体；或者V和Z通过额外的3-5个原子连接形成含有5-7个原子的环状基团，可选地含有1个杂原子，取代为羟基、酰氧基、烷氧羰氧基或芳氧羰氧基，连接到距离磷的两个O基团都有3个原子的碳原子上；或者V和Z通过额外的3-5个原子连接形成一个环状基团，可选地含有1个杂原子，融合到与连接到磷的O的β和γ位的芳基团上；或者V和W通过额外的3个碳原子连接形成一个可选地取代的含有6个碳原子的环状基团，并取代有来自羟基、酰氧基、烷氧羰氧基、烷基硫酰氧基和芳基羰氧基的一种取代基，连接到距离磷的一个O上的碳原子上；或者Z和W通过额外的3-5个原子连接形成一个环状基团，可选地含有一个杂原子，且V必须是芳基、取代芳基、杂芳基或取代杂芳基；或者W和W′通过额外的2-5个原子连接形成一个环状基团，可选地含有0-2个杂原子，且V必须是芳基、取代芳基、杂芳基或取代杂芳基；Z选自由—CHR2OH、—CHR2OC（O）R3、—CHR2OC（S）R3、—CHR2OC（S）OR3、—CHR2OC（O）SR3、—CHR2OCO2R3、—OR2、—SR2、—CHR2N3、—CH2芳基、—CH（芳基）OH、—CH（CH═CR22）OH、—CH（C≡CR2）OH、—R2、—NR22、—OCOR3、—OCO2R3、—SCOR3、—SCO2R3、—NHCOR2、—NHCO2R3、—CH2NH芳基、—（CH2）p—OR12和—（CH2）p—SR12；p是整数2或3；具有以下限制条件：a）V、Z、W、W′不全为—H；b）当Z为—R2时，至少有一个V、W或W′不为—H、烷基、芳基烷基或脂环烷基；R2选自由R3和—H组成的群体；R3选自由烷基、芳基、脂环烷基和芳基烷基组成的群体；R12选自由—H和较低酰基组成的群体；M选自连接到PO32−、P2O63−或P3O94−的群体中的生物活性剂，并通过碳、氧、硫或氮原子连接到式I中的磷；以及其药学上可接受的前药和盐。